Yeztugo Cost: What the Twice-Yearly PrEP Shot Actually Costs in 2026
Yeztugo carries a list price near $28,000 a year, and for its first six months on the market most insurers refused to cover it. That has changed substantially. Here's the current coverage picture, what you'd pay, and how to get it for nothing.
What's in this guide
Start PrEP now, sort out Yeztugo later
Yeztugo access is still uneven and prior authorization can take weeks. Starting on daily oral PrEP today means you're protected while that process runs. MISTR gets most patients on PrEP at $0 — consultation, labs, medication, and delivery included.
ANDR735
Using this code at signup helps us achieve our mission of getting free PrEP out to all who need it. It costs you nothing and never changes what you pay.
Yeztugo (lenacapavir) is the twice-yearly HIV prevention injection Gilead brought to market in June 2025 after an FDA priority review. Two shots a year, roughly 99% risk reduction in trials, and in the pivotal studies it outperformed daily oral PrEP — largely because people took every dose.
The problem was never the science. It was the invoice.
The price, plainly
Published cash prices for the subcutaneous solution have run around $14,000 per dose, which is where the roughly $28,000 annual figure comes from. There is also an initiation phase involving oral lenacapavir tablets alongside the first injections, which carries its own cost of roughly $2,300 for a four-tablet supply at cash prices.
Nobody should be paying these numbers. But for the first several months after approval, plenty of people effectively were — because their plans simply refused to cover the drug at all, leaving cash price as the only option.
Insurance coverage: what changed in 2026
This is the part most articles about Yeztugo get wrong, because they were written in 2025 and never updated.
When Yeztugo launched, pharmacy benefit managers balked at the price. PBMs are the intermediaries that decide which drugs make it onto a plan's formulary, and the three largest — CVS Caremark, Cigna's Express Scripts, and UnitedHealth's Optum Rx — process the large majority of specialty prescriptions in the country. CVS Health said publicly in August 2025 that it would not cover Yeztugo, pointing to cost and to the availability of cheaper alternatives. Optum kept it off its premium formulary on the same grounds.
Advocates pushed hard through late 2025. By January 2026, Caremark — the last major holdout — reversed and added Yeztugo to its formulary. Gilead stated at that point that it had secured roughly 85% insurance coverage for the drug, including UnitedHealth, Express Scripts, and CVS.
Coverage is not universal, though. Some individual plans and some Blue Cross Blue Shield affiliates still classify Yeztugo as not medically necessary for PrEP on the grounds that covered alternatives exist. Others place it on a high specialty tier with prior authorization and step therapy — meaning you may have to document a failure or intolerance of oral PrEP first.
What you'd actually pay
| Your situation | Expected cost |
|---|---|
| Commercial plan, Yeztugo on formulary | $0. PrEP is a USPSTF Grade A preventive service, so a covered form of PrEP must be provided with no cost sharing — no copay, no deductible. |
| Commercial plan, prior authorization required | $0 once approved. Your prescriber submits the PA. Budget several weeks and stay on oral PrEP meanwhile. |
| Commercial plan, Yeztugo excluded | Request a formulary exception with documented medical necessity. If denied, the Gilead co-pay card covers up to $7,200/year — which does not cover $28,000. Oral PrEP or Apretude is the practical answer here. |
| Uninsured | Apply to Gilead's Medication Assistance Program through Advancing Access. Eligible uninsured patients can receive Gilead medications at no cost. |
| Medicaid | Varies by state. Some state Medicaid programs and PrEP-DAPs cover injectables; many do not yet cover Yeztugo specifically. Check your state program. |
| Medicare | Part B covers PrEP as a preventive service without cost sharing, including injectable forms, along with associated counseling and testing. |
Don't wait unprotected while paperwork clears
Prior authorization for injectable PrEP frequently takes weeks. Oral PrEP through MISTR starts in days and costs most patients nothing. Switching to an injectable later is straightforward once your coverage is confirmed.
ANDR735
Using this code at signup helps us achieve our mission of getting free PrEP out to all who need it. It costs you nothing and never changes what you pay.
How to get Yeztugo at $0
Confirm current formulary status — again
Call the number on your insurance card and ask specifically whether Yeztugo (lenacapavir) is on formulary for PrEP, and whether prior authorization applies. If you asked in 2025, ask again; several major payers reversed course.
Enroll with Gilead Advancing Access
Advancing Access runs benefits verification, prior authorization support and appeals, the co-pay savings program for commercially insured patients, and the Medication Assistance Program for uninsured patients. Start there rather than trying to navigate the pharmacy yourself.
Have your prescriber document medical necessity
If your plan requires step therapy or has excluded the drug, the exception request needs clinical reasoning — adherence difficulty with daily dosing, intolerance, or a specific reason an every-two-month injection isn't workable.
Ask about the administration fee separately
The injection itself is a billable service. Under the ACA preventive rules that should also be at no cost sharing when performed in network, but it is billed under different codes than the drug and is a common source of surprise charges.
Stay on oral PrEP throughout
The single most common mistake is stopping PrEP while a prior authorization is pending. Protection ends immediately; the paperwork takes weeks.
Yeztugo vs. Apretude vs. daily pills on cost
| Yeztugo | Apretude | Generic oral PrEP | |
|---|---|---|---|
| Dosing | Injection every 6 months | Injection every 2 months | Daily pill |
| Doses per year | 2 | 6 | 365 |
| List price/year | ~$28,000 | ~$22,000 | ~$300–$850 cash |
| Manufacturer | Gilead | ViiV Healthcare | Multiple generics |
| Assistance program | Gilead Advancing Access | ViiVConnect | Widely available; often unnecessary |
| Payer coverage | Expanded sharply in 2026 | Well established | Universal |
| Clinic visits | 2/year for injection | 6/year for injection | None for dosing; quarterly labs |
If clinic burden is what you're optimizing for, Yeztugo's two visits a year is a genuinely different experience from Apretude's six. We go deeper on the clinical comparison in Yeztugo vs. Apretude and on switching between the two.
Where you can actually get it
Yeztugo requires a healthcare professional to administer it — subcutaneous injection into the abdomen — so it cannot be shipped to your door the way oral PrEP can. Practical access points are HIV clinics, infectious disease practices, some primary care offices, Ryan White clinics, and community health centers. Gilead maintains a list of authorized specialty pharmacies for acquisition.
Telehealth PrEP platforms handle oral PrEP well, but injectables are a different logistics problem. MISTR, for instance, does not currently offer Yeztugo through its telehealth service; where it's available it's through physical storefront locations. If an injectable is your goal, plan on an in-person relationship with a clinic. Our injectable PrEP guide covers how to find one.
Why $40 generics exist elsewhere
You may have seen headlines about lenacapavir generics priced around $40 per year. Those are real, and they are also not available to you.
In September 2025, Indian manufacturers Dr. Reddy's Laboratories and Hetero Labs announced they would sell generic lenacapavir for roughly $40 a year beginning in 2027, under licensing arrangements aimed at low- and middle-income countries. That pricing exists specifically to enable access in countries where the US list price is unthinkable. It does not extend to the United States, where Gilead holds patent protection, and importing unapproved medication is not a legal or safe workaround.
The gap between $40 and $28,000 for the identical molecule is a legitimate policy scandal. It is not, unfortunately, a route to cheaper PrEP for an American reader today.
Is it worth pursuing over generic PrEP?
Honest answer: for many people, no — and that's fine.
Generic oral PrEP delivers roughly 99% risk reduction for sexual transmission when taken as prescribed, costs $26–$70 a month in cash, and is free through countless programs. The reason lenacapavir outperformed oral PrEP in trials is adherence, not pharmacology. If you reliably take a daily pill, the marginal benefit is small.
Yeztugo is genuinely transformative for people where daily dosing fails — unstable housing, privacy concerns about pill bottles, chaotic schedules, or simply a long history of missed doses. If that describes you, the coverage fight is worth having. If it doesn't, generic oral PrEP started this week beats a perfect injectable started in three months.
Free PrEP while you pursue the shot
MISTR covers consultation, at-home or in-person labs, medication, and discreet delivery at $0 for most patients, insured or not, in all 50 states, D.C., and Puerto Rico. Note that Yeztugo itself is not currently available through MISTR's telehealth service.
ANDR735
Using this code at signup helps us achieve our mission of getting free PrEP out to all who need it. It costs you nothing and never changes what you pay.
Frequently asked questions
How much does Yeztugo cost?
The list price is roughly $28,000 per year, or about $14,000 per injection, with two injections annually. That is the sticker price, not what patients typically pay. With insurance coverage or Gilead's assistance programs, most people should pay $0.
Does insurance cover Yeztugo now?
Much more than it did at launch. All three major pharmacy benefit managers — CVS Caremark, Express Scripts, and Optum Rx — had added Yeztugo by early 2026, with Caremark reversing its refusal in January 2026. Gilead reported roughly 85% payer coverage at that point. Coverage still isn't universal, and prior authorization is common.
Why did CVS refuse to cover Yeztugo?
CVS Health said in August 2025 that it would not cover Yeztugo, citing the roughly $28,000 annual list price and the availability of lower-cost alternatives including daily oral PrEP. After sustained pressure from HIV advocates, CVS Caremark reversed that position and added the drug to its formulary in January 2026.
How much does Yeztugo cost without insurance?
Around $28,000 a year at cash prices, which is not a realistic out-of-pocket purchase. Uninsured patients should apply to Gilead's Medication Assistance Program through Advancing Access, which can provide Gilead medications at no cost to eligible patients.
Can I get Yeztugo through telehealth?
Not generally. Yeztugo must be injected by a healthcare professional, so it requires an in-person visit twice a year. MISTR does not currently offer Yeztugo through its telehealth service. HIV clinics, infectious disease practices, Ryan White clinics, and community health centers are the usual access points.
Is Yeztugo better than Apretude?
They're both highly effective long-acting injectables. The main practical difference is dosing frequency: Yeztugo is every six months, Apretude every two months. That's two clinic visits a year versus six. Apretude has more established payer coverage and a longer track record; Yeztugo has the lighter schedule.
What is the $40 generic lenacapavir I read about?
Dr. Reddy's Laboratories and Hetero Labs announced in September 2025 that they would sell generic lenacapavir for roughly $40 a year starting in 2027, under licensing arrangements for low- and middle-income countries. That pricing does not apply in the United States, where Gilead holds patent protection.
Should I wait for Yeztugo or start oral PrEP now?
Start now. Prior authorization for injectable PrEP routinely takes weeks, and protection from oral PrEP begins within days. There is no clinical downside to starting on a daily pill and transitioning to an injectable once coverage is confirmed — and going unprotected during the wait is a real risk.
Sources
Gilead Sciences, Yeztugo prescribing information and cost/coverage resources · Drugs.com price guide for Yeztugo (subcutaneous solution and oral tablets) · The Hill, reporting on Yeztugo formulary decisions and PBM coverage, January 2026 · Positively Aware, reporting on the CVS Caremark formulary reversal, January 2026 · Reuters reporting on Dr. Reddy's and Hetero generic lenacapavir pricing, September 2025 · Blue Cross Blue Shield of Mississippi medical policy on lenacapavir · U.S. Preventive Services Task Force PrEP recommendation and PHS Act § 2713 · Gilead Advancing Access program terms.
Prices and formulary decisions change frequently. Confirm current coverage with your plan. This guide is general information, not medical advice.